
|Videos|December 6, 2017
Looking Back: Ovarian Cancer in 2017
Author(s)OLIVER DORIGO, M.D., PH.D.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.
Advertisement
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on exciting developments in the ovarian cancer field from 2017. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes these drugs have great potential in ovarian cancer treatment.
Advertisement
Related Content
Advertisement




First-Line Treatment Choice and Altering Resistance in EGFR-Mutant NSCLC
Published: | Updated:

Latest CME
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
2
Managing Daraxonrasib: Key Takeaways and Efficacy Insights for Oncology Nurses
3
Addressing Financial Toxicity: Team-Based Workflows in Oncology Care
4
ASCO Releases First Living Guideline for Recurrent Ovarian Cancer Care
5












































